These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 12163621)

  • 21. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
    Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
    Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease.
    Iizuka T; Kameyama M
    Geriatr Gerontol Int; 2017 Jun; 17(6):951-958. PubMed ID: 27215917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease.
    Yoshida T; Ha-Kawa S; Yoshimura M; Nobuhara K; Kinoshita T; Sawada S
    Ann Nucl Med; 2007 Jul; 21(5):257-65. PubMed ID: 17634843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parametric mapping of cerebral blood flow deficits in Alzheimer's disease: a SPECT study using HMPAO and image standardization technique.
    Imran MB; Kawashima R; Awata S; Sato K; Kinomura S; Ono S; Yoshioka S; Sato M; Fukuda H
    J Nucl Med; 1999 Feb; 40(2):244-9. PubMed ID: 10025830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease.
    Defebvre LJ; Leduc V; Duhamel A; Lecouffe P; Pasquier F; Lamy-Lhullier C; Steinling M; Destée A
    J Nucl Med; 1999 Jun; 40(6):956-62. PubMed ID: 10452310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of linearization correction on statistical parametric mapping (SPM): a 99mTc-HMPAO brain perfusion SPECT study in mild Alzheimer's disease.
    Ansar MA; Osaki Y; Kazui H; Oku N; Takasawa M; Kimura Y; Begum NN; Ikejiri Y; Takeda M; Hatazawa J
    Ann Nucl Med; 2006 Oct; 20(8):511-7. PubMed ID: 17134017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
    J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors.
    Oshima E; Terada S; Sato S; Ikeda C; Oda K; Inoue S; Kawada K; Yokota O; Uchitomi Y
    Psychiatry Res; 2014 Dec; 224(3):319-23. PubMed ID: 25453992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
    Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting regional cerebral blood flow changes in Alzheimer's patients after milameline treatment: activation or baseline SPECT?
    Zheng XM
    J Nucl Med Technol; 2002 Sep; 30(3):118-22. PubMed ID: 12186960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period].
    Turon-Estrada A; López-Pousa S; Gelada-Batlle E; Garre-Olmo J; Lozano-Gallego M; Hernández-Ferràndiz M; Fajardo-Tibau C; Morante-Muñoz V; Vilalta-Franch J
    Rev Neurol; 2003 Mar 1-15; 36(5):421-4. PubMed ID: 12640593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.